Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    CNS Pharmaceuticals Inc.

    NASDAQ: CNSP · Real-Time Price · USD
    1.26
    0.11 (9.57%)
    At close: May 15, 2025, 3:58 PM
    1.20
    -4.39%
    After-hours: May 15, 2025, 04:53 PM EDT
    9.57%
    Bid 1.18
    Market Cap 3.7M
    Revenue (ttm) 1.57K
    Net Income (ttm) -14.86M
    EPS (ttm) -1943.5
    PE Ratio (ttm) n/a
    Forward PE -0.29
    Analyst Buy
    Ask 1.25
    Volume 530,274
    Avg. Volume (20D) 1,851,532
    Open 1.10
    Previous Close 1.15
    Day's Range 1.10 - 1.26
    52-Week Range 0.77 - 800.00
    Beta 0.77

    About CNSP

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol CNSP
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for CNSP stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    2 days ago
    +12.4%
    CNS Pharmaceuticals shares are trading higher afte... Unlock content with Pro Subscription
    1 month ago
    -51.78%
    CNS Pharmaceuticals shares are trading lower after the company announced the primary analysis of its clinical trial evaluating Berubicin for the treatment of recurrent or progressive Glioblastoma Multiforme did not demonstrate statistically significant superiority in overall survival, the primary endpoint.
    news image

    1 day ago · accessnewswire.com

    CNS Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

    HOUSTON, TX / ACCESS Newswire / May 13, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for pri...

    news image

    2 days ago · accessnewswire.com

    CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel, Late Stage Abeotaxane, TPI 287

    Company advancing plans to develop TPI 287, a novel, late stage abeotaxane that appears to cross the blood-brain barrier and has published clinical efficacy data in glioblastoma multiforme (GBM) Manag...

    news image

    1 month ago · accessnewswire.com

    CNS Pharmaceuticals Reports Full Year 2024 Financial Results

    Company has one year of cash to fund operations Company advancing plans to develop TPI 287, a novel, late stage abeotaxane that is potentially blood brain barrier permeable with published clinical eff...

    news image

    1 month ago · benzinga.com

    CNS Pharma's Cancer Drug Misses Survival Goal But May Offer Fewer Side Effects

    CNS Pharmaceuticals, Inc.  CNSP on Tuesday announced the primary analysis of its clinical trial evaluating Berubicin for recurrent or progressive Glioblastoma Multiforme (GBM), an aggressive form of b...

    news image

    1 month ago · accessnewswire.com

    CNS Pharmaceuticals Announces Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma Multiforme

    Berubicin showed clinically relevant outcomes comparable to Lomustine across multiple endpoints, but not a statistically significant difference in overall survival, the primary endpoint. The safety pr...

    news image

    2 months ago · accessnewswire.com

    CNS Pharmaceuticals Provides Update on Current Cash Position and NASDAQ Listing

    Cash on hand provides over one year of runway to fund expected operations HOUSTON, TX / ACCESS Newswire / February 26, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopha...

    news image

    2 months ago · accessnewswire.com

    CNS Pharmaceuticals to Present at the 18th Annual European Life Sciences CEO Forum

    Webcast presentation Wednesday, February 26th at 3:20 PM CET HOUSTON, TX / ACCESS Newswire / February 20, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical c...

    news image

    2 months ago · accessnewswire.com

    CNS Pharmaceuticals, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

    On-demand video webcast now available here HOUSTON, TX / ACCESS Newswire / February 19, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializin...

    news image

    2 months ago · accessnewswire.com

    CNS Pharmaceuticals Announces Reverse Stock Split

    HOUSTON, TX / ACCESS Newswire / February 19, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments fo...

    news image

    2 months ago · accessnewswire.com

    CNS Pharmaceuticals to Present at 6th Glioblastoma Drug Development Summit

    HOUSTON, TX / ACCESS Newswire / February 18, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments fo...

    Add to Watchlist